Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)

Market Cap	35.43B +92.7%
Revenue (ttm)	928.01M -12.0%
Net Income	-301.59M
EPS	-0.29
Shares Out	919.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,317,860
Average Volume	18,861,383
Open	36.25
Previous Close	36.71
Day's Range	36.11 - 39.14
52-Week Range	15.75 - 71.71
Beta	0.12
RSI	37.68
Earnings Date	Apr 25, 2026

About SHE:300255

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. The company offers crude heparin sodium, heparin sodium API, heparin sodium injections, low molecular weight heparin calcium injections, enoxaparin sodium injections, nandroparin calcium injection, dalteparin sodium API and injections, and other products. The company was found...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 1,254
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300255

Financial Performance

In 2024, SHE:300255's revenue was 1.03 billion, a decrease of -26.92% compared to the previous year's 1.41 billion. Losses were -249.48 million, -79.88% less than in 2023.